Opentrons Banks $40M Series E to Push AI-Run Lab Automation

Opentrons Labworks has raised $40 million in a Series E round led by healthcare investor Avego, with BroadOak Capital Partners also participating, to scale the robotics, software, and data infrastructure behind its lab automation platform.

The New York-based company stated that the capital will fund AI-driven experimental execution, broader automation capabilities, and expansion into new markets and geographies. Opentrons also intends to speed up protocol development through its software stack and deepen integration of its instruments into the wider lab automation ecosystem.

What is the money actually buying?

According to the company, the funds will support systems in which artificial intelligence and robotics jointly design, execute, and learn from scientific experiments. That is a portfolio claim worth scrutinizing: Opentrons did not disclose a timeline, headcount targets, or revenue figures alongside the raise. The round's valuation was also not disclosed.

The deployment base, at least, is verifiable at scale. Opentrons reports more than 11,000 robots installed in laboratories across over 80 countries, serving academic groups, diagnostic labs, and global pharmaceutical companies. The company did not break down that installed base by segment or instrument type, which limits how much weight the figure can carry in a procurement comparison.

Earlier this year, Opentrons announced it is using Nvidia's Isaac and Cosmos AI platforms to generate training data for physical AI-enabled laboratory robotics. The new funding extends that work toward what the company calls autonomous science — experiments run directly by AI on its hardware.

What did the investors say?

James Flexner, managing partner at Avego, framed the investment as a bet on where experimental work is heading. "Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data," Flexner said. "We see a significant opportunity for autonomous science to converge around Opentrons' platform."

Opentrons CEO James Atwood, PhD, made a stronger claim about the company's position. "We made lab automation accessible for any lab, and our systems are built for AI to run experiments directly," Atwood said. "That is why autonomous science is standardizing on Opentrons."

The standardization claim is the CEO's, not an independently measured result. No customer adoption data, retention figures, or third-party benchmarks accompanied the announcement to substantiate it.

Why it matters for R&D budgets

For lab managers, the raise signals continued vendor consolidation around AI-executed workflows rather than standalone pipetting hardware. Opentrons' pitch — accessible automation plus AI-driven protocol execution — targets labs that want usable experimental data without dedicated automation engineering staff.

The competitive question left unanswered is differentiation. Several vendors are racing to pair robotics with AI experiment design, and Opentrons has not published comparative performance data for its AI-driven execution against manual or scripted workflows.

Avego's involvement points to healthcare as the near-term growth market. The company says expansion into new geographies is planned, though it named no specific regions.

With $40 million in hand and an Nvidia partnership already in place, Opentrons' next test will be converting its installed base of 11,000-plus robots into evidence that AI-run experiments deliver measurably faster, cheaper science.